Lipson Evan J
Department of Oncology; Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center; Baltimore, MD USA.
Oncoimmunology. 2013 Apr 1;2(4):e23661. doi: 10.4161/onci.23661.
The blockade of immune regulatory checkpoints is emerging as a powerful anticancer strategy. We recently reported long-term results from the first-in-human clinical trial of anti-PD1 antibody-based immunotherapy, demonstrating durable tumor control off-therapy in subjects affected by colorectal and kidney cancer, as well as successful re-induction therapy in a melanoma patient.
免疫调节检查点阻断正成为一种强大的抗癌策略。我们最近报告了基于抗PD1抗体的免疫疗法首次人体临床试验的长期结果，证明该疗法对受结直肠癌和肾癌影响的患者具有持久的肿瘤控制效果，并且在一名黑色素瘤患者中成功进行了再诱导治疗。
